Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Pulmonary function test and videocapillaroscopy abnormalities mean values at baseline, 12 months and 24 months

From: Effects of treatment with rituximab on microcirculation in patients with long-term systemic sclerosis

Variable Time 0 Time 1 Time 2 p*
FVC (mean %) 65.0 64.0 68.5 0.65
DLco (mean %) 52.3 53.5 60.0 0.06
Giant capillaries (score 0–3) 0.03 0.02 0.01 0.66
Hemorrhages (score 0–3) 0.10 0.06 0.06 > 0.99
Capillary loss (score 0–3) 1.06 1.05 1.32 0.18
Abnormally shaped capillaries (score 0–3) 0.35 0.50 0.58 > 0.99
Architecture (score 0–3) 0.62 0.59 0.79 0.66
MES 2.04 2.17 2.62 0.93
  1. Observation: The non-random sample was small to demonstrate statistical differences. *It was used the Friedman test which is non-parametric statistical test
  2. FVC forced vital capacity, DLCO diffusion capacity of the lung for carbon monoxide, MES microangiopathy evolution score, range 0 (absence of the abnormality) to 3